Altimmune (ALT) Post-$5 Valuation: Catalysts, Clinical Data, and Risk Analysis

Altimmune’s (ALT) stock price recently exceeded $5, validating the core claim from a November 23 Reddit post [6]. The company’s lead drug pemvidutide showed 58%/52% MASH resolution in 24-week trials [4], though fibrosis improvement was not statistically significant—consistent with delayed antifibrotic effects of GLP-1 therapies [4]. Upcoming Q4 2025 catalysts (48-week trial data, FDA meeting) are expected to drive further valuation changes [5]. Analysts forecast 250% upside [3], supported by BioSpace’s estimate of $1B+ peak revenue for MASH [2].

1. The 24-week trial’s fibrosis result may not be definitive, as antifibrotic effects often take longer [4].
2. The Reddit post’s 21% short interest claim remains unconfirmed [3].
3. Analyst upside depends on successful catalyst outcomes (trial data, FDA approval) [3].

• Positive 48-week trial data could unlock significant valuation upside [3].
• Strategic partnerships or licensing deals may boost investor confidence [4].
  
  Risks
  :
• Clinical trial failure (e.g., no fibrosis improvement in 48-week data) [4].
• FDA rejection or delayed approval [5].
• Valuation pullback if catalysts do not meet expectations [3].

• Current price: $5.26 (as of 2025-11-29) [0].
• Clinical: 58% MASH resolution (1.2mg dose) in Phase IIb [4].
• Catalysts: Q4 2025 48-week IMPACT trial data and FDA End of Phase 2 meeting [5].
• Analyst outlook: 250% upside predicted [3].